These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 28833562

  • 1. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [Abstract] [Full Text] [Related]

  • 2. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.
    JAMA Neurol; 2017 Aug 01; 74(8):941-949. PubMed ID: 28604926
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
    Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R.
    CNS Drugs; 2018 Apr 01; 32(4):387-398. PubMed ID: 29532440
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
    Pajo AT, Espiritu AI, Jamora RDG.
    Neurodegener Dis Manag; 2019 Aug 01; 9(4):205-215. PubMed ID: 31392922
    [Abstract] [Full Text] [Related]

  • 7. Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Paik J, Keam SJ.
    CNS Drugs; 2018 Aug 01; 32(8):797-806. PubMed ID: 30088203
    [Abstract] [Full Text] [Related]

  • 8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov 01; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
    Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D, ALLAY-LID I and ALLAY-LID II study groups.
    Parkinsonism Relat Disord; 2022 Mar 01; 96():65-73. PubMed ID: 35227940
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, NS-Park CIC Network.
    Neurology; 2014 Jan 28; 82(4):300-7. PubMed ID: 24371304
    [Abstract] [Full Text] [Related]

  • 14. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.
    Mov Disord; 2017 Jun 28; 32(6):893-903. PubMed ID: 28370447
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
    Hauser RA, Kremens DE, Elmer LW, Kreitzman DL, Walsh RR, Johnson R, Howard R, Nguyen JT, Patni R.
    J Parkinsons Dis; 2019 Jun 28; 9(3):591-600. PubMed ID: 31081793
    [Abstract] [Full Text] [Related]

  • 16. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
    Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W.
    Mov Disord; 2010 Jul 30; 25(10):1357-63. PubMed ID: 20198649
    [Abstract] [Full Text] [Related]

  • 17. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.
    Mov Disord; 2016 Jul 30; 31(7):1049-54. PubMed ID: 26990766
    [Abstract] [Full Text] [Related]

  • 18. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM.
    Parkinsonism Relat Disord; 2005 Nov 30; 11(7):449-52. PubMed ID: 16154788
    [Abstract] [Full Text] [Related]

  • 19. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ, Macdonald L, Mcauley D, Wallis W.
    Clin Neuropharmacol; 2000 Nov 30; 23(2):82-5. PubMed ID: 10803797
    [Abstract] [Full Text] [Related]

  • 20. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
    Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, Patni R.
    Parkinsonism Relat Disord; 2019 Mar 30; 60():118-125. PubMed ID: 30292734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.